Market Newsdesk

MILWAUKEE, July 9, 2021 /PRNewswire/ — MGIC Investment Corporation (NYSE: MTG) has announced plans to release its second quarter 2021 financial results after the market closes on Wednesday August 4, 2021.  A conference call/webcast has been scheduled for 10:00 a.m. Eastern Time on Thursday August 5, 2021 to discuss the Company’s results for the quarter ended June 30, 2021.

Individuals interested in joining by telephone should dial 1-866-834-4126 ten minutes before the conference call begins. The call is also being webcast and can be accessed via the company’s investor website found at http://mtg.mgic.com under Newsroom. A replay of the webcast will be available on the company’s website through September 5, 2021.

The Company also today issued selected operating statistics of the primary mortgage insurance of its insurance subsidiaries for the month of June 2021. The summary is also available on the company’s investor website under Newsroom, Press Releases.

The information concerning new delinquency notices and cures is compiled from reports received from loan servicers. The level of new notice and cure activity reported in a particular month can be influenced by, among other things, the date on which a servicer generates its report, the accuracy of the data provided by servicers, the number of business days in a month, transfers of servicing between loan servicers, and whether all servicers have provided the reports in a given month.  Notices of delinquency are typically reported to us when loans are two payments past due (for example, for June we report as a new delinquency any delinquent loan that missed its May 1st (or earlier) payment that was not previously reported to us in May).  We expect the number of delinquencies will continue to be influenced by various factors related to the COVID-19 pandemic, including its length and severity, efforts to reduce its transmission, the resulting level of unemployment, and the impact of various government initiatives to mitigate the resulting economic harm.

The information concerning the percentage of loans in forbearance is based on the most recent information provided by Fannie Mae and Freddie Mac (the GSEs), as well as loan servicers, and we believe substantially all reported forbearances are related to COVID-19.  While the forbearance information provided by the GSEs refers to delinquent loans in forbearance as of the prior month-end, the information provided by loan servicers may be more current.

About MGIC
Mortgage Guaranty Insurance Corporation (“MGIC”) (www.mgic.com), the principal subsidiary of MGIC Investment Corporation, serves lenders throughout the United States, Puerto Rico, and other locations helping families achieve homeownership sooner by making affordable low-down-payment mortgages a reality through the use of private mortgage insurance.

From time to time MGIC Investment Corporation releases important information via postings on its corporate website, and via postings on MGIC’s website for information related to underwriting and pricing, and intends to continue to do so in the future. Such postings include corrections of previous disclosures, and may be made without any other disclosure. Investors and other interested parties are encouraged to enroll to receive automatic email alerts and Really Simple Syndication (RSS) feeds regarding new postings. Enrollment information for MGIC Investment Corporation alerts can be found at https://mtg.mgic.com/shareholder-services/email-alerts. For information about our underwriting and rates, see https://www.mgic.com/underwriting.

Cautionary Note Regarding Forward-Looking Statements
This press release may contain forward looking statements. Forward looking statements consist of statements which relate to matters other than historical fact, including matters that inherently refer to future events and involve certain important risks and uncertainties, any of which could cause our actual results to differ materially from those expressed in our forward-looking statements. More information about the risks, uncertainties and assumptions affecting the company can be found in the risk factors included as Exhibit 99 to our Annual Report on Form 10-Q for the quarter ended March 31, 2021, and in other filings we make with the Securities and Exchange Commission.  No investor should rely on the fact that such statements are current at any time other than the time at which this press release was issued

View original content:https://www.prnewswire.com/news-releases/mgic-investment-corporation-schedules-2nd-quarter-2021-earnings-call-and-releases-monthly-operating-statistics-301328211.html

SOURCE MGIC Investment Corporation

INDIANAPOLIS, July 9, 2021 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced new Phase 2 data showing that gene expression changes induced by mirikizumab in patients with ulcerative colitis (UC) over a 12-week induction treatment were maintained for up to one year. These gene transcript changes, which were unique among those who responded to mirikizumab compared to placebo, were associated with mucosal healing, indicating that mirikizumab affects a distinct molecular healing pathway, compared to the spontaneous healing that occurred among those who responded to placebo.

Mirikizumab is being studied in Phase 3 trials for UC and Crohn’s disease (CD), two forms of inflammatory bowel disease that can cause serious and debilitating symptoms, and disruptions in daily life.

A separate analysis of patients with moderate to severe UC evaluated meaningful improvement of bowel urgency, a common symptom of UC that is associated with higher levels of disease activity, decreased work productivity and worse quality of life. These results are being presented virtually at the Congress of the European Crohn’s and Colitis Organisation (ECCO), July 8-10, 2021.

Mirikizumab Showed Early and Sustained Gene Expression Changes Associated with Mucosal Healing in UC for Up to One Year

In a previously-published Phase 2 study evaluating patients with UC, mirikizumab down-regulated several gene transcripts associated with inflamed mucosa and up-regulated gene transcripts correlated with healthy mucosa and markers of functional healing after 12 weeks, as defined by clinical disease indices of endoscopy and histology. 

In this analysis, a set of differentially-expressed gene transcripts were identified in patients who responded to mirikizumab that were not found in those who responded to placebo at 12 weeks. Of the modulated genes, 71% (n=63) were present only in patients who responded to mirikizumab, 5.6% (n=5) were present only in those who responded to placebo, and 23.6% (n=21) were present in both groups. Effect size estimates were also examined to account for differences in sample size and associated power between treatment groups. The set of gene transcripts regulated by mirikizumab correlated with UC disease activity indices, demonstrating consistency of these molecular changes across symptomatic, clinical, endoscopic and histologic indices of UC disease activity.

The results observed at 12 weeks were maintained for up to one year in patients receiving mirikizumab. For methodology, see the “About the Studies” section below. 

“In the first clinical study of an anti-IL-23p19 therapy in ulcerative colitis to evaluate gene expression on this large scale, mirikizumab demonstrated an ability to down-regulate the gene transcripts associated with inflammation and up-regulate transcripts associated with mucosal healing in ulcerative colitis, with changes maintained for up to one year,” said Walter Reinisch, Director of the Clinical IBD Study Group, Department of Gastroenterology and Hepatology, Medical University of Vienna. “These results support the continued development of mirikizumab as a potential treatment option for ulcerative colitis, given the importance of mucosal healing and functional healing as key treatment goals for this difficult-to-treat disease.”

Patients with UC Reported on Definition of Meaningful Change in Bowel Urgency

Bowel urgency, the sudden or immediate need for a bowel movement, is one of the most distressing symptoms experienced by patients with UC. In this qualitative study of patients with moderate to severe UC, patients defined both bowel urgency severity and what would be a meaningful improvement in bowel urgency based on an 11-point numeric rating scale (NRS).

In this study, half of patients with UC (50%, n=10) reported that a 1-point change on the urgency NRS would be a meaningful change, indicating improved emotional well-being and greater confidence to leave the home or do their work.

A quarter of respondents (25%, n=5) indicated that a 2-point improvement in the urgency NRS was required to be considered meaningful, and another 25% of respondents (n=5) noted that a 3-point change or more was needed to achieve improvements in quality of life.

Importantly, among the 75% of patients who endorsed a 1 to 2-point change in urgency NRS, initial scores on the urgency NRS ranged from 2 to 9, indicating that this amount of change was meaningful regardless of the severity of an individual’s bowel urgency. For methodology, see the “About the Studies” section below. 

“We are very excited to present these findings at ECCO, which provide one of the first analyses from the patient perspective on the impact of bowel urgency and what would constitute a meaningful change,” said Prentice Stovall, Jr., Global Development Leader, Immunology at Lilly. “Given the impact that bowel urgency has on an individual’s ability to work and overall quality of life, this analysis will help us further understand the experience of people with UC and the potential impact of our treatments on this burdensome and debilitating symptom.”

About The Studies

• Mirikizumab-Induced Transcriptome Changes in Patient Biopsies at Week 12 Are Maintained Through Week 52 in Patients with Ulcerative Colitis
  Patients who achieved clinical response at 12 weeks, as measured by a decrease in 9-point Mayo subscore (rectal bleeding, stool frequency, endoscopy) of ≥2 points and ≥35% from baseline, with either a decrease of rectal bleeding subscore of ≥1 or an RB subscore of 0 or 1) continued onto maintenance mirikizumab treatment. Patients given placebo in induction who achieved clinical response continued on placebo in the maintenance period. In this study, colonic biopsies from 52 patients were obtained at Weeks 0, 12 and 52 from the most affected area ≥30 cm from the anal verge (mirikizumab, n=31, placebo, n=7). Of those patients, 31 were 200 mg mirikizumab responders and seven responded to placebo. Transcript changes at Week 12 from baseline in the placebo and mirikizumab arms were clustered into differentially expressed genes using the Bayesian Limma R-package. Differentially expressed genes which maintained their Week 12 expression level through Week 52 in both the placebo and mirikizumab arms were identified and designated as similarly expressed genes. Overall, the safety profile at 52 weeks was consistent with that of mirikizumab in studies of UC and with the class.
• A Qualitative Study Exploring Meaningful Improvement in Bowel Urgency among Adults with Moderate to Severe Ulcerative Colitis
  In this qualitative study assessing meaningful improvement in bowel urgency based on a NRS, in-depth interviews were conducted in the United States with 20 adults with clinician-confirmed moderate to severe UC. Using an 11-point NRS developed specifically to assess bowel urgency severity, participants were asked to define levels of bowel urgency (where 0=no urgency and 10=worst possible urgency). Participants were also asked to describe what would be a meaningful improvement based on how this change would impact their daily life.

About Mirikizumab
Mirikizumab is a humanized IgG4 monoclonal antibody that binds to the p19 subunit of interleukin 23. Mirikizumab is being studied for the treatment of immune diseases, including ulcerative colitis and Crohn’s disease.

About Ulcerative Colitis
Ulcerative colitis is a chronic inflammatory bowel disease that affects the colon. UC occurs when the immune system sends white blood cells into the lining of the intestines, where they produce chronic inflammation and ulcerations. There is an unmet need for additional treatment options for UC that provide meaningful symptom relief, including bowel urgency, and deliver sustained clinical remission.

About Eli Lilly and Company
Lilly is a global health care leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at lilly.com and lilly.com/newsroom.  P-LLY

Lilly Forward-Looking Statement
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about mirikizumab as a potential treatment for patients with ulcerative colitis and/or Crohn’s disease and reflects Lilly’s current beliefs and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development, and commercialization. Among other things, there can be no guarantee that future study results will be consistent with study results to date, that mirikizumab will prove to be a safe and effective treatment or that mirikizumab will receive regulatory approvals or be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly’s most recent Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/mirikizumab-up-regulates-genes-associated-with-mucosal-healing-in-ulcerative-colitis-for-up-to-one-year-in-phase-2-study-301324815.html

SOURCE Eli Lilly & Company

FORT WORTH, Texas, July 9, 2021 /PRNewswire/ — AZZ Inc. (NYSE: AZZ), a global provider of metal coating solutions, welding solutions, specialty electrical equipment and highly engineered services today announced financial results for the first quarter of fiscal year 2022, ended May 31, 2021. 

First Quarter Overview:

• Strong year-over-year financial results
• Reported diluted earnings per share of $0.88, up 319.0%, and
• Reported net income of $22.3 million, up 303.1% versus last year’s period
• Sales of $229.8 million, up 7.8% versus last year’s period
• Metal Coatings segment versus same quarter, prior year:
• Sales of $127.7 million, up 7.3%
• Operating Income of $31.6 million, up 25.9%
• Operating margins of 24.7%, compared with 21.1% in prior year quarter
• Infrastructure Solutions segment versus same quarter, prior year:
• Sales of $102.1 million, up 8.3%
• Operating Income of $9.6 million, versus loss of $(1.0) million in prior year quarter
• Operating margins of 9.4% compared with loss of (1.1)% in prior year quarter
• Declared quarterly cash dividend in the amount of $0.17 per common share
• Repurchased 125,770 shares, totaling $6.3 million

Management Discussion

Tom Ferguson, President and Chief Executive Officer of AZZ, commented, “We are off to a solid start in fiscal 2022 with strong operating performance in the first quarter, including sales increasing 7.8%, operating income up 114.5% and net income up threefold. The solid financial results reflect the strength of our businesses and our team doing an outstanding job executing at a high level across the board, continuing our momentum of growth and improving operational efficiencies.”

“Our Metal Coatings segment delivered solid operating results with sales of $127.7 million, up 7.3%, and operating margin of 24.7%, up 360 basis points versus 21.1% in last year’s first quarter.  Segment level results were driven by improved market conditions, customer mix, price, and operational improvement initiatives.”

Mr. Ferguson continued, “During the first quarter, our Infrastructure Solutions segment had sales of $102.1 million, up 8.3% and operating margin of 9.4%, a tenfold improvement, compared to last year’s COVID impacted first quarter. Results were driven by solid operating improvement in our global welding solutions business, as refiners returned to performing turnarounds. We are gaining confidence for an improved second half of the year with increased domestic and international quoting activity for turnarounds, positioning AZZ for a potentially strong fiscal 2022. I want to thank all our employees for their hard work and dedication in delivering outstanding results, as well as continuing to provide exceptional service to our customers during the quarter.” 

First Quarter Results

For the first quarter of fiscal year 2022, the Company reported sales of $229.8 million compared to $213.3 million for the comparable period last year, an increase of 7.8%.  Operating income increased to $30.7 million, or 114.5%, compared to $14.3 million in last year’s comparable three-month period. Net income for the current quarter increased $16.8 million to $22.3 million, or $0.88 per diluted share compared to $5.5 million, or $0.21 per diluted share for the same quarter in the prior fiscal year.  The provision for income taxes of $7.6 million reflects an effective tax rate of 25.5% for the three months ended May 31, 2021, as compared to $4.7 million, or 45.8%, for the prior year comparable period.  Bookings for the three-month period increased to $229.8 million, compared to $174.9 million for the same quarter last year. 

Metal Coatings Segment

For the first quarter of fiscal year 2022, Metal Coatings segment sales increased 7.3% to $127.7 million and operating income increased 25.9% to $31.6 million compared to $119.0 million and $25.1 million respectively, for the same period in the prior fiscal year.  The higher sales for the quarter were primarily attributable to improved price realization and customer mix.  Operating margins for the quarter were 24.7%, an improvement of 360 basis points compared to 21.1% in the first quarter of fiscal year 2021.  Operating margin improvement was driven by both improved price realization in the current quarter, and a continued focus on operations excellence.

Infrastructure Solutions Segment

For the first quarter of fiscal year 2022, Infrastructure Solutions segment sales increased 8.3% to $102.1 million as compared to $94.3 million in the same quarter of the prior year.  Operating income for the first quarter of fiscal year 2022 totaled $9.6 million as compared to an operating loss of $(1.0) million in the prior year quarter.  The increase in net sales, operating income and margin for the three-month period was primarily attributable to improved market conditions within our Industrial platform, which saw an improvement in turnaround activity in both the U.S. and international markets.

Fiscal Year 2022 Guidance

Mr. Ferguson added, “Due to the improved market conditions for many of our end markets, we have revised our previously issued fiscal 2022 sales and earnings guidance. We now anticipate sales will be in the range of $855 million to $935 million and earnings per share to be in the range of $2.65 to $3.05 per diluted share for fiscal year 2022. This compares to the previous guidance of sales in the range $835 million to $935 million and earnings in the range of $2.45 to $2.95 per diluted share for fiscal year 2022.” 

“As previously stated for fiscal 2022, we remain highly focused on growing our Metal Coatings segment and building our Infrastructure Solutions backlog in enclosures, switchgear and welding solutions.  The underlining fundamentals of our business remain strong providing us the foundation to aggressively pursue growth opportunities that fit our strategic plan. As part of our corporate commitment to Trust, Respect, Accountability, Integrity, Teamwork and Safety (“TRAITS”), we continue to carefully manage our workforce to ensure a safe and healthy operating environment, while flexing our capacity to better match our customers improved demand for our products and services.” 

“We continue to actively pursue initiatives to enhance shareholder value, drive growth, and accelerate our strategy to become predominately a metal coatings company.  The previously announced board-led strategic review of our portfolio and capital allocation is complete, and we are actively pursuing multiple recommendations that align with and support our strategy.  We are a much stronger company today and well-positioned to meet the growing demands for infrastructure improvements in the U.S and globally,” concluded Mr. Ferguson. 

Conference Call Details

AZZ Inc. will conduct a conference call to discuss financial results for the first quarter of fiscal year 2022 today, Friday July 9, 2021, at 11:00 A.M. ET. Interested parties can access the conference call by dialing (844) 855-9499 or (412) 317-5497 (international). A webcast of the call will be available on the Company’s Investor Relations page at http://www.azz.com/investor-relations.   

A replay of the call will be available for three days at (877) 344-7529 or (412) 317-0088 (international), confirmation # 10157738, or for 30 days at http://www.azz.com/investor-relations.

There will be a slide presentation accompanying today’s event. The Company’s slide presentation for the call will be available on the Investor Relations page at http://www.azz.com/investor-relations.

About AZZ Inc.

AZZ Inc. is a global provider of galvanizing and a variety of metal coating solutions, welding solutions, specialty electrical equipment and highly engineered services to a broad range of markets, including but not limited to the power generation, transmission, distribution, refining and industrial markets. The Company’s Metal Coatings segment is a leading provider of metal finishing solutions for corrosion protection, including hot dip galvanizing, spin galvanizing, powder coating, anodizing and plating, to the North American steel fabrication industry. The Company’s Infrastructure Solutions segment is dedicated to delivering safe and reliable transmission of power from generation sources to end customers, and automated weld overlay solutions for corrosion and erosion mitigation to critical infrastructure in the energy and waste management markets worldwide.

Safe Harbor Statement

Certain statements herein about our expectations of future events or results constitute forward-looking statements for purposes of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995. You can identify forward-looking statements by terminology such as “may,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology. Such forward-looking statements are based on currently available competitive, financial and economic data and management’s views and assumptions regarding future events. Such forward-looking statements are inherently uncertain, and investors must recognize that actual results may differ from those expressed or implied in the forward-looking statements. Certain factors could affect the outcome of the matters described herein. This press release may contain forward-looking statements that involve risks and uncertainties including, but not limited to, changes in customer demand for our products and services, including demand by the power generation markets, electrical transmission and distribution markets, the industrial markets, and the metal coatings markets.  In addition, within each of the markets we serve, our customers and our operations could potentially be adversely impacted by the ongoing COVID-19 pandemic.  We could also experience fluctuations in prices and raw material cost, including zinc and natural gas which are used in the hot dip galvanizing process; supply-chain vendor delays; customer requested delays of our products or services; delays in additional acquisition opportunities; currency exchange rates; adequacy of financing; availability of experienced management and employees to implement AZZ’s growth strategy; a downturn in market conditions in any industry relating to the products we inventory or sell or the services that we provide; economic volatility or changes in the political stability in the United States and other foreign markets in which we operate; acts of war or terrorism inside the United States or abroad; and other changes in economic and financial conditions.  AZZ has provided additional information regarding risks associated with the business in AZZ’s Annual Report on Form 10-K for the fiscal year ended February 28, 2021 and other filings with the Securities and Exchange Commission (“SEC”), available for viewing on AZZ’s website at


www.azz.com


 and on the SEC’s website at


www.sec.gov


.  You are urged to consider these factors carefully in evaluating the forward-looking statements herein and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. These statements are based on information as of the date hereof and AZZ assumes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise.

Company Contact:    
David Nark, Senior Vice President of Marketing, Communications and Investor Relations 
AZZ Inc.
(817) 810-0095
www.azz.com

Investor Contact:

Joe Dorame, Managing Partner
Lytham Partners
(602) 889-9700
www.lythampartners.com

—Financial tables on the following page—

 

 

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/azz-inc-reports-results-for-first-quarter-of-fiscal-year-2022-generates-eps-of-0-88-and-revises-guidance-301328529.html

SOURCE AZZ Inc.

FARMINGTON, Conn., July 9, 2021 /PRNewswire/ — Otis Worldwide Corporation (NYSE: OTIS) will host a conference call on Monday, July 26, 2021, at 8:30 a.m. EDT. Otis President & CEO Judy Marks and Executive Vice President & CFO Rahul Ghai will discuss the company’s second quarter results and the outlook for 2021.

Participants are encouraged to listen live via webcast on www.otis.com. To join by phone, dial +1-877-735-3703 and an operator will place you on hold until the conference begins. Please allow 15 minutes before the scheduled start time to connect to the teleconference.

A corresponding presentation and news release as well as additional investor materials will be available on www.otis.com prior to the call and a recording of the call will be made available on the website later in the day.

About Otis

Otis is the world’s leading elevator and escalator manufacturing, installation and service company. We move 2 billion people a day and maintain approximately 2.1 million customer units worldwide, the industry’s largest Service portfolio. Headquartered in Connecticut, USA, Otis is 69,000 people strong, including 40,000 field professionals, all committed to meeting the diverse needs of our customers and passengers in more than 200 countries and territories worldwide. For more information, visit www.otis.com and follow us on LinkedIn, Instagram, Facebook and Twitter @OtisElevatorCo.

 

 

View original content:https://www.prnewswire.com/news-releases/otis-second-quarter-2021-earnings-advisory-301328258.html

SOURCE Otis Worldwide Corporation

JUNO BEACH, Fla., July 9, 2021 /PRNewswire/ — NextEra Energy Partners, LP (NYSE: NEP) today announced that it plans to report second-quarter 2021 financial results before the opening of the New York Stock Exchange on Friday, July 23, 2021, in a news release to be posted on its website at www.NextEraEnergyPartners.com/FinancialResults. An advisory news release will be issued over PR Newswire the morning of July 23, with a link to the financial results news release on NextEra Energy Partners’ website. As previously announced, NextEra Energy Partners will make available its financial results only on its website.

Jim Robo, chairman and chief executive officer of NextEra Energy Partners, Rebecca Kujawa, chief financial officer of NextEra Energy Partners, and other members of the senior management team will discuss the second-quarter 2021 financial results during an investor presentation to be webcast live, beginning at 9 a.m. ET on July 23. Results for NextEra Energy, Inc. (NYSE: NEE) also will be discussed during the same investor presentation.

The listen-only webcast will be available on NextEra Energy Partners’ website by accessing the following link: www.NextEraEnergyPartners.com/FinancialResults. The financial results news release and the slides accompanying the presentation may be downloaded at www.NextEraEnergyPartners.com/FinancialResults, beginning at 7:30 a.m. ET on the day of the webcast. A replay will be available for 90 days by accessing the same link as listed above.

NextEra Energy Partners, LP
NextEra Energy Partners, LP (NYSE: NEP) is a growth-oriented limited partnership formed by NextEra Energy, Inc. (NYSE: NEE). NextEra Energy Partners acquires, manages and owns contracted clean energy projects with stable, long-term cash flows. Headquartered in Juno Beach, Florida, NextEra Energy Partners owns interests in geographically diverse wind and solar projects in the U.S. as well as natural gas infrastructure assets in Texas and Pennsylvania. For more information about NextEra Energy Partners, please visit: www.NextEraEnergyPartners.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/nextera-energy-partners-lp-announces-date-for-release-of-second-quarter-2021-financial-results-301328447.html

SOURCE NextEra Energy Partners, LP

JUNO BEACH, Fla., July 9, 2021 /PRNewswire/ — NextEra Energy, Inc. (NYSE: NEE) today announced that it plans to report second-quarter 2021 financial results before the opening of the New York Stock Exchange on Friday, July 23, 2021, in a news release to be posted on the company’s website at www.NextEraEnergy.com/FinancialResults. The company will issue an advisory news release over PR Newswire the morning of July 23, with a link to the financial results news release on the company’s website. As previously communicated, the company will make available its financial results only on its website.

Jim Robo, chairman and chief executive officer of NextEra Energy, Rebecca Kujawa, executive vice president, finance and chief financial officer of NextEra Energy, and other members of the company’s senior management team will discuss the company’s second-quarter 2021 financial results during an investor presentation to be webcast live, beginning at 9 a.m. ET on July 23. Results for NextEra Energy Partners, LP (NYSE: NEP) also will be discussed during the same investor presentation.

The listen-only webcast will be available on NextEra Energy’s website by accessing the following link: www.NextEraEnergy.com/FinancialResults. The financial results news release and the slides accompanying the presentation may be downloaded at www.NextEraEnergy.com/FinancialResults, beginning at 7:30 a.m. ET on the day of the webcast. A replay will be available for 90 days by accessing the same link as listed above.

NextEra Energy, Inc.
NextEra Energy, Inc. (NYSE: NEE) is a leading clean energy company headquartered in Juno Beach, Florida. NextEra Energy owns Florida Power & Light Company, which is the largest rate-regulated electric utility in the United States as measured by retail electricity produced and sold, and serves more than 5.6 million customer accounts, supporting more than 11 million residents across Florida with clean, reliable and affordable electricity. NextEra Energy also owns a competitive clean energy business, NextEra Energy Resources, LLC, which, together with its affiliated entities, is the world’s largest generator of renewable energy from the wind and sun and a world leader in battery storage. Through its subsidiaries, NextEra Energy generates clean, emissions-free electricity from seven commercial nuclear power units in Florida, New Hampshire and Wisconsin. A Fortune 200 company and included in the S&P 100 index, NextEra Energy has been recognized often by third parties for its efforts in sustainability, corporate responsibility, ethics and compliance, and diversity. NextEra Energy is ranked No. 1 in the electric and gas utilities industry on Fortune’s 2021 list of “World’s Most Admired Companies” and received the S&P Global Platts 2020 Energy Transition Award for leadership in environmental, social and governance. For more information about NextEra Energy companies, visit these websites: www.NextEraEnergy.com, www.FPL.com, www.GulfPower.com, www.NextEraEnergyResources.com.                     

View original content to download multimedia:https://www.prnewswire.com/news-releases/nextera-energy-announces-date-for-release-of-second-quarter-2021-financial-results-301328445.html

SOURCE NextEra Energy, Inc.